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(CLI) eventually require amputation. In spite of clinically
successful revascularisation patients rarely return to their
pre-morbid status, and often report no improvement in
their functional outcomes, which may be due to an un-
derlying musculopathy. Non-haematopoietic EPO-de-
rivatives have been designed to retain only tissue-protective
functions of EPO. We hypothesised that ARA-290 (EPO-de-
rivative) may have tissue-protective potential that would
represent a novel therapeutic adjunct in patients with CLI.
Methods: The effect of EPO and ARA-290 in mediating
cytoprotection was assessed ﬁrstly in vitro using skeletal
myoblasts isolated from CLI and control donors, and a
model of simulated ischaemia. Characterisation of CLI
myoblasts was also performed, to assess their contractile,
migratory and proliferative ability. Subsequently, an in vivo
murine model of hindlimb ischaemia, which recapitulates
the muscular pathology observed in CLI patients, was used
to assess the potential of ARA-290 to improve functional,
histological and perfusion outcomes.
Results: Skeletal myoblasts were successfully isolated from
CLI patients for the ﬁrst time. CLI myoblasts and myotubes
exhibited increased proliferative capacity but reduced
migratory and contractile function and importantly a
reduced susceptibility to a second ischaemic-insult
compared with control myoblasts and myotubes. EPO and
ARA-290 treatment led to signiﬁcant improvements in
myoblasts and myotube function and survival via the JAK2/
STAT3, PI3k/Akt and NFkB signalling pathways. In vivo,
animals treated with EPO and ARA-290 demonstrated
improved functional, histological and perfusion outcomes
compared to vehicle-control treated animals.
Conclusion: These studies demonstrate the potential of EPO
and its derivatives to protect tissues and cells from
ischaemic-injury and encourages the development of novel
pharmacological therapies for use in patients with “no op-
tion” CLI or severe functional deﬁcit.
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Introduction: Immature plaque neovessels contribute to
atherosclerotic plaque instability and intraplaque hemor-
rhage by leaking erythrocytes and leukocytes in the plaque.
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2),
together with the angiopoietin (Ang)-Tie2 system, regulates
the maturation of growing neovessels. We have previously
shown that murine vein graft lesions exhibit massive plaqueneovascularization and that leaky vessels and intraplaque
hemorrhage contribute to lesion growth. We hypothesized
that blockade of VEGFR2 results in more mature plaque
microvessels and less intraplaque hemorrhage.
Methods: Donor caval veins were engrafted in carotid ar-
teries of recipient hypercholesterolemic ApoE3*Leiden mice
(n ¼ 14/group). Mice were treated at day 14, 17, 21 and 25
with VEGFR2 blocking antibodies (DC101) or control IgG
antibodies (10 mg/kg). At day 28 mice were sacriﬁced for
histological analysis of the vein grafts.
Results: Morphometric analysis revealed a striking 50%
decrease in vein graft segments that expressed intraplaque
haemorrhage in the form of leaky vessels in the DC101
treated group. This was accompanied by a signiﬁcant 25-
fold decrease in extravasated erythrocytes. Furthermore,
lesions that exhibit intraplaque hemorrhage showed a
strong increase in Ang-2, indicative for immature neo-
vessels. VEGFR2 blockade however, did not affect the neo-
vessel density in the lesions (control 52  19 neovessels/
section; DC101 63  25 neovessels/section). Interestingly,
the vein graft lesion area in the DC101 group was signiﬁ-
cantly reduced with 32% compared to the control group.
Moreover, plaque stability was clearly increased in DC101
treated mice, determined by a 25% reduction in macro-
phage content, a 50% increase in collagen content and a
120% increase in SMC content.
Conclusion: Blockade of VEGFR2 leads to reduced intra-
plaque hemorrhage, decreased vein graft lesion area and
increased plaque stability. This identiﬁes plaque neo-
vascularization as an attractive target for the treatment of
unstable atherosclerotic diseases.
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Introduction: TLR4-mediated mobilisation and activation of
pro-inﬂammatory Ly6Chi monocytes is crucial for effective
post-ischemic neovascularisation, i.e. arteriogenesis and
angiogenesis. Therefore, we aimed to investigate the role of
the TLR4-accessory molecule RP105 (CD180) in neo-
vascularisation. RP105 has been identiﬁed as a negative
regulator of TLR4 signalling in monocytes. Using immuno-
histochemical analyses, we found that RP105+monocytes are
present in the perivascular space of remodelling collateral
arterioles. As RP105 inhibits TLR4 signalling, we hypothesized
that RP105 deﬁciency would lead to an unrestrained TLR4-
mediated inﬂammatory response and hence to enhanced
neovascularisation and blood ﬂow recovery after ischemia.
Methods: RP105/ and wildtype mice were subjected to
hind limb ischemia and blood ﬂow recovery was followed
by Laser Doppler Perfusion Imaging during four weeks.
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that blood ﬂow recovery was severely impaired in RP105/
 mice. Immunohistochemistry showed that both arterio-
genesis and angiogenesis were reduced in these mice
compared to wildtype animals. However, both in vivo and
ex vivo analyses showed that circulatory pro-arteriogenic
Ly6Chi monocytes were more readily activated in RP105/
 mice. FACS analyses in blood and tissue samples from
wildtype mice showed that Ly6Chi monocytes migrate to
the affected muscle tissues following induction of hind limb
ischemia. Although Ly6Chi monocytes were more readily
activated in RP105/ mice, migration into the ischemic
tissues was severely hampered and instead, Ly6Chi mono-
cytes accumulated in their storage compartments, bone
marrow and spleen, of RP105/ mice. In vitro studies
showed that activation of monocytes with LPS reduces their
migratory ability, indicating that a timely, well-regulated
activation of monocytes is crucial for effective
neovascularisation.
Conclusion: The lack of TLR4 regulation in RP105/ mice
results in an unrestrained inﬂammatory response, leading
to systemic monocyte over-activation. Monocyte activation
reduces their migratory ability and thus, this premature,
systemic activation of pro-inﬂammatory Ly6Chi monocytes
results in reduced inﬁltration of Ly6Chi monocytes in
affected tissues after ischemia and consequently in reduced
arteriogenesis and angiogenesis. Therefore, a tightly regu-
lated inﬂammatory response is crucial for effective neo-
vascularisation and blood ﬂow recovery after ischemia.
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Introduction: Ischemia and reperfusion (I/R) of the spinal
cord are central problems of aortic surgery procedures e.g.
aneurysm repair. In a large animal model we showed in the
past that erythropoietin (EPO) attenuates the morphological
signs of spinal cord I/R-injury and improves neurological
function, but observation time was only 10 hours short. This
small animal model with optimized clamping time evaluates
the beneﬁt of perioperative i.v. EPO administration and
gives answer to the question of the clinical outcome up to 4
days.
Methods: To evaluate the optimal clamping time 36 New
Zealand White Rabbits were used. Unlike other animal
species rabbits have a pure segmental blood supply for the
spinal cord, therefore reproducible paraplegia can be per-
formed by infrarenal clamping alone. The ischemic times
ranged from 15 over 17 to 20, 22 and 25 min to deﬁne best
ﬁtting clamping time. Afterwards rabbits received eithervehicle (control, n ¼ 10) or EPO (n ¼ 10; 5000 IU/kg) over
the last 30 min before clamping and during the ﬁrst 30
minutes of reperfusion. Intraoperatively blood pressure
(invasive), heart rate, oxygen saturation and temperature
were recorded. In addition, blood samples were taken
before and after aortic clamping for studies on senescence
and apoptosis parameters. Clinical neurological examina-
tions were performed using a modiﬁed Tarlov score every
twelve hours. After 96 h the entire spinal cord was har-
vested for histological examination.
Results: After 96 h postoperative observation period animals
of the 15 min clamping group showed a Tarlov score of 3.65
 1.55; 17 min 4  1.75; 20 min 1.5  2.22; 22 min 0 
1.59; 25 min 0  0. Histological and clinical ﬁndings were
signiﬁcantly correlated, p ¼ 0.007. Therefore a clamping time
of 22 minutes was deﬁned for further experiments. The
following study groups consisted of control animals (NaCl; n
¼ 10) and EPO treated animals (n ¼ 10) challenged with 22
minutes aortic clamping. While the control animals showed
no neuronal function at all (median ¼ 0), the EPO group
standed out with improved spinal cord function (median ¼
4,25) after 36 hours of reperfusion. This beneﬁt was lost
again after 96 hours of reperfusion (median ¼ 0).
Conclusion: This model is an ideal setup for therapeutic
studies on ischemia and reperfusion injury (I/R) after aortic
crossclamping. EPO showed impressive beneﬁts in ischemic
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Introduction: Fibrosis is an initial step in the development of
atherosclerotic lesions, hallmarked by myoﬁbroblasts entering
the tunica media and forming a ﬁbrous cap. Vasa vasorum in
the adventitia consist of endothelial cells, surrounded by per-
icytes. Pericytes can be regarded as cells with stem cell like
properties and the capacity to differentiate into myoﬁbro-
blasts. Although it is known that shear stress induces athero-
sclerotic lesions, nothing is known about its impact on
pericytes. Herein, we investigate the effect of shear stress on
pericytes and focus on differentiation into myoﬁbroblasts.
Methods: Primary human pericytes (PCs) were isolated
from donor fatty tissue and cultured in DMEM + 10% FCS.
Primary cells were characterised by immunoﬂuorescent (IF)
staining (NG2, CD90, CD105, CD44, CD45, CD73, CD146,
CD31, and PDGFR-beta). Endothelial cells (HUVEC) or PC
were seeded into ﬂow chambers and subjected to laminar
ﬂow at low 10 dyn, high 30 dyn and no shear stress rates for
48 h (n ¼ 3/group). RNA was extracted and analysed by
qPCR for tissue inhibitor of metalloproteinase 3, versican
